Huang Siyuan, O'Donnell Kevin P, Keen Justin M, Rickard Mark A, McGinity James W, Williams Robert O
Division of Pharmaceutics, College of Pharmacy, |The University of Texas at Austin, 2409 University Avenue, Mail Stop A1920, Austin, Texas, USA.
The Dow Chemical Company, Dow Pharma & Food Solutions, Midland, Michigan, USA.
AAPS PharmSciTech. 2016 Feb;17(1):106-19. doi: 10.1208/s12249-015-0395-9. Epub 2015 Sep 4.
Hypromellose is a hydrophilic polymer widely used in immediate- and modified-release oral pharmaceutical dosage forms. However, currently available grades of hypromellose are difficult, if not impossible, to process by hot melt extrusion (HME) because of their high glass transition temperature, high melt viscosity, and low degradation temperature. To overcome these challenges, a modified grade of hypromellose, AFFINISOL™ HPMC HME, was recently introduced. It has a significantly lower glass transition temperature and melt viscosity as compared to other available grades of hypromellose. The objective of this paper is to assess the extrudability and performance of AFFINISOL™ HPMC HME (100LV and 4M) as compared to other widely used polymers in HME, including HPMC 2910 100cP (the currently available hypromellose), Soluplus®, Kollidon® VA 64, and EUDRAGIT® E PO. Formulations containing polymer and carbamazepine (CBZ) were extruded on a co-rotating 16-mm twin-screw extruder, and the effect of temperature, screw speed, and feed rate was investigated. The performance of the solid dispersions was evaluated based on Flory-Huggins modeling and characterized by differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), Raman spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and dissolution. All formulations extruded well except for HPMC 2910 100cP, which resulted in over-torqueing the extruder (machine overloading because the motor cannot provide efficient energy to rotate the shaft). Among the HME extrudates, only the EUDRAGIT® E PO formulation was crystalline as confirmed by DSC, XRD, and Raman, which agreed with predictions from Flory-Huggins modeling. Dissolution testing was conducted under both sink and non-sink conditions. Sink dissolution testing in neutral media revealed that amorphous CBZ in the HME extrudates completely dissolved within 15 min, which was much more rapid than the time for complete dissolution of bulk CBZ (60 min) and EUDRAGIT® E PO solid dispersion (more than 6 h). Non-sink dissolution in acidic media testing revealed that only CBZ contained in the AFFINISOL™ HPMC HME, and EUDRAGIT® E PO solid dispersions rapidly supersaturated after 15 min, reaching a twofold drug concentration compared to the CBZ equilibrium solubility. In summary, AFFINISOL™ HPMC HME 100LV and AFFINISOL™ HPMC HME 4M are useful in the pharmaceutical HME process to increase wetting and dissolution properties of poorly water-soluble drugs like CBZ.
羟丙甲纤维素是一种亲水性聚合物,广泛应用于速释和缓释口服药物剂型。然而,由于其高玻璃化转变温度、高熔体粘度和低降解温度,目前可用的羟丙甲纤维素等级即使不是不可能,也很难通过热熔挤出(HME)工艺进行加工。为了克服这些挑战,最近推出了一种改性等级的羟丙甲纤维素,即AFFINISOL™ HPMC HME。与其他可用等级的羟丙甲纤维素相比,它的玻璃化转变温度和熔体粘度显著更低。本文的目的是评估AFFINISOL™ HPMC HME(100LV和4M)与HME中其他广泛使用的聚合物(包括HPMC 2910 100cP(目前可用的羟丙甲纤维素)、Soluplus®、Kollidon® VA 64和EUDRAGIT® E PO)相比的可挤出性和性能。将含有聚合物和卡马西平(CBZ)的制剂在一台同向旋转的16毫米双螺杆挤出机上进行挤出,并研究温度、螺杆速度和进料速率的影响。基于弗洛里-哈金斯模型对固体分散体的性能进行评估,并通过差示扫描量热法(DSC)、X射线粉末衍射(XRD)、拉曼光谱、傅里叶变换红外(FTIR)光谱和溶出度进行表征。除了HPMC 2910 100cP外,所有制剂都能顺利挤出,HPMC 2910 100cP导致挤出机扭矩过大(机器过载,因为电机无法提供足够能量来旋转螺杆)。在HME挤出物中,只有EUDRAGIT® E PO制剂经DSC、XRD和拉曼证实为结晶态,这与弗洛里-哈金斯模型的预测结果一致。在漏槽和非漏槽条件下都进行了溶出度测试。在中性介质中的漏槽溶出度测试表明,HME挤出物中的无定形CBZ在15分钟内完全溶解,这比原料药CBZ(60分钟)和EUDRAGIT® E PO固体分散体(超过6小时)完全溶解的时间要快得多。在酸性介质中的非漏槽溶出度测试表明,只有AFFINISOL™ HPMC HME和EUDRAGIT® E PO固体分散体中含有的CBZ在15分钟后迅速过饱和,药物浓度达到CBZ平衡溶解度的两倍。总之,AFFINISOL™ HPMC HME 100LV和AFFINISOL™ HPMC HME 4M在药物HME工艺中可用于提高难溶性药物(如CBZ)的润湿性和溶出性能。